SunBio PEGylation technology and PEG products have played a crucial role in many successfully marketed biosimilar, biopharmaceutical and medical devices products worldwide.
The healthcare products under development at SunBio are listed in the table.
|Biosimilar||PEG-filgrastim Biosimilar||Marketed||2018 EU
|PEG-EPO Biosimilar||Preclinical||2023 (forecast)|
|Medical Device||Xerostomia Treatment
|2019.11 FDA Approved||2020(forecast)|
|Viscosupplement for Arthritic Knee
|2021 FDA filing planned||2022 (forecast)|
|Biopharmaceutical||Brain Stroke Treatment (SB1)||Preclinical||2025 (forecast)|
|Diabetic Retinopathy Treatment (SB2)||Preclinical||2025 (forecast)|
|Anemia Treatment (SB7)||Preclinical||2028 (forecast)|
|PEG Product||PEG Derivatives Manufacture and Sales||Marketed||Worldwide|